SUVEN PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 834 INR | +1.20% |
|
+15.74% | +15.38% |
| Jun. 19 | Transcript : Sapala Organics Private Limited, Suven Pharmaceuticals Limited - M&A Call | |
| Jun. 14 | Suven Pharmaceuticals to Acquire 67.5% Stake in Sapala Organics | MT |
| Sales 2024 | 10.51B 126M | Sales 2025 * | 11.53B 138M | Capitalization | 212B 2.54B |
|---|---|---|---|---|---|
| Net income 2024 | 3B 35.98M | Net income 2025 * | 3.4B 40.78M | EV / Sales 2024 | 16.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 18.4 x |
| P/E ratio 2024 |
57.4
x | P/E ratio 2025 * |
62.2
x | Employees | 1,193 |
| Yield 2024 * |
0.21% | Yield 2025 * |
0.18% | Free-Float | 87.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Suven Pharmaceuticals Limited
| 1 day | +1.20% | ||
| 1 week | +15.74% | ||
| Current month | +3.73% | ||
| 1 month | +35.10% | ||
| 3 months | +26.56% | ||
| 6 months | +14.63% | ||
| Current year | +15.38% |
1 week
729.30
836.40
1 month
600.05836.40
Current year
585.20836.40
1 year
477.65836.40
3 years
390.50836.40
5 years
87.60836.40
10 years
87.60836.40
| Managers | Title | Age | Since |
|---|---|---|---|
Sudhir Singh
CEO | Chief Executive Officer | - | 23-09-28 |
Himanshu Agarwal
DFI | Director of Finance/CFO | 30 | Dec. 31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 23-09-28 | |
Shweta Jalan
BRD | Director/Board Member | 48 | Nov. 08 |
| Director/Board Member | 62 | Nov. 08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 114 M€ | +6.41% | - | |
| 0.00% | 32 M€ | +4.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 824.8 | -1.11% | 285,692 |
| 24-07-02 | 834 | +1.20% | 349,213 |
| 24-07-01 | 824.1 | +2.50% | 784,545 |
| 24-06-28 | 804 | +2.11% | 1,126,132 |
| 24-06-27 | 787.4 | +7.97% | 3,673,466 |
End-of-day quote NSE India S.E., July 01, 2024
More quotes
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Companyâs wholly owned subsidiary is Suven Pharma Inc.
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
834
INR
Average target price
670.5
INR
Spread / Average Target
-19.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.38% | 2.54B | |
| +55.55% | 816B | |
| +40.45% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.04% | 238B | |
| +1.43% | 222B | |
| +13.53% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- SUVENPHAR Stock
